A cDNA library was constructed in 2gt 10 using mRNA purified from cells infected with parainfluenza virus type 2 (PIV2). Virus-specific clones were identified by screening the library with 32p-labelled cDNA probes made from randomly primed vRNA. Clones containing the haemagglutinin-neuraminidase (HN) gene were identified by sequence comparisons with known parainfluenza virus HN gene sequences. The largest HN clone isolated had a nucleic acid sequence of 2065 bp with a single long open reading frame encoding a protein of 571 amino acids. The HN protein has nine predicted glycosylation sites and an amino-terminal membrane-spanning region. The PIV2 HN protein shares 43 % amino acid identity with the HN protein of simian virus 5 and 40 % with mumps virus, 30 % of the amino acids being common to all three viruses.
Introduction
Human parainfluenza virus type 2 (PIV2) is a member of the parainfluenza virus genus (Kingsbury et al., 1978; Pringle, 1987) , causing acute respiratory infections in children (Wright, 1984) . Other members of the genus include parainfluenza viruses types 1, 3 and 4, mumps virus, simian virus 5 (SV5), Sendai virus, Newcastle disease virus (NDV) and bovine parainfluenza virus type 3. The linear single-stranded RNA genomes of these viruses encode a minimum of six polypeptides. The nucleoprotein (NP), phosphoprotein (P), matrix protein (M) and the large protein (L) are located internally within the virion, while the haemagglutinin-neuraminidase (HN) and fusion protein (F) are envelope glycoproteins. The 'P gene' may encode a second protein that is cysteine-rich and which is usually referred to as protein V (Thomas et al., 1988) . Some parainfluenza viruses also encode a small hydrophobic protein (SH) . Although this protein is located in the plasma membrane of infected cells it is probably excluded from virions (Hiebert et al., 1988) and its function remains unknown.
Serological studies have shown that PIV2, SV5 and mumps virus are antigenically related and appear to form a subgroup within the parainfluenza viruses. Although the greatest degree of antigenic identity is observed between the internal virus proteins (Goswami & Russell, 1983; Ito et al., 1987; Randall & Young, 1988; Tsurudome et al., 1989) , studies using polyclonal antisera have also demonstrated weak antigenic cross-reactivity between the HN proteins of these viruses (Ito et al., 1987; Randall & Young, 1988) . However, there are major antigenic differences between SV5, PIV2 and mumps.
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For example, of 67 monoclonal antibodies directed against the HN protein of either SV5 or PIV2 (Goswami & Russell, 1983; Randall & Young, 1988; Rydbeck et aL, 1988; Tsurudome et al., 1989) only two appear to be weakly cross-reactive with the heterologous virus (Goswami & Russell, 1983; Rydbeck et al., 1988) . Nevertheless, the antigenic cross-reactivities observed between PIV2, SV5 and mumps have led to some difficulty in interpreting epidemiological data designed to examine the incidence of human infection with SV5 (Hsiung, 1972; Goswami et al., 1984) and its possible role in particular diseases e.g. multiple sclerosis (Goswami et al., 1987; Vandvick & Norrby, 1989) .
Sequence analysis of selected genes of SV5 and mumps virus has been reported (for example it has been shown that the HN proteins of these viruses share 44% amino acid identity ; Hiebert et al., 1985; Waxam et al., 1988) but no data are available for PIV2. In order to investigate further the evolutionary relationship between PIV2 and other parainfluenza viruses and to provide a basis for future studies on the molecular immunology of PIV2, we have begun a programme to sequence specific PIV2 genes. Here we report on the construction of a cDNA library to PIV2 made in 2gtl0 from mRNA isolated from virus-infected cells. Clones containing full-length inserts of the HN gene have been identified and a representative clone has been sequenced.
Methods
Cells and viruses. Vero cells (Flow Laboratories) were grown as monolayers in 75 cm z tissue culture flasks, 150 mm 2 Petri dishes and in rotating 80 oz Winchester bottles in Dulbecco's modification of Eagle's tissue culture medium (MEM) supplemented with 10~ newborn calf serum. Cells were also grown in the same medium on Cytodex I beads (Pharmacia). The prototype isolate of PIV2 was obtained from the Central Public Health Laboratories, Colindale, London, U.K.
Purification, eDNA synthesis and radiolabelling of genomic RNA. Vero cells, grown either on Cytodex beads or in 80 oz Winchester bottles, were infected with 0-1 p.f.u, of PIV2 per cell for 2 h at 37 °C. The inoculum was then removed and replaced with fresh tissue culture medium without calf serum and the cells were incubated at 37 °C until 100% c.p.e, was observed (27 to 30 h post-infection). The medium was harvested and clarified by centrifugation at 10000g for 15 rain. The supernatant was layered over a 30~ (w/v) sucrose cushion and virus pelleted by centrifugation at 70000 g, in a Beckman SW28 rotor, for 2 h at 4 °C. Genomic RNA was extracted from the virus pellet as previously described by Spriggs et al. (1986) . 32p radiolabelling of eDNA was carried out by random priming the vRNA as described by Feinberg & Vogelstein (1983) , with the modification that avian myeloblastosis virus (AMV) reverse transcriptase (Pharmacia) was used instead of the Klenow fragment of Escherichia coli DNA polymerase I.
Preparation ofmRNAfor eDNA cloning. Vero cells, grown in 150 mm 2 Petri dishes, were infected with PIV2 at a multiplicity of 0.1 p.f.u, for 1 h at 37 °C. The inoculum was then removed and the cells incubated, at 37 °C for 24 h, in the presence or absence of actinomycin D (5 lag/ml; Paterson et al., 1984) , in MEM without calf serum. Cells were then harvested and the mRNA was extracted using either Amersham (RPN.1264), or Pharmacia (27-9258-01) RNA extraction kits and purified by oligo(dT) column chromatography.
cDNA synthesis, construction and characterization of PIV2 libraries in 2gtlO. Two eDNA libraries were prepared in the bacteriophage vector ;tgt 10. eDNA synthesis, second strand synthesis and ligation of linkers was carried out using either Amersham (RPN.1256; library 1) or Pharmacia (27-9260-01; library 2) eDNA synthesis and cloning kits. Packaging of the ligated products used either Amersham (RPN. 1257) or Stratagene (200211) kits. Phage-containing inserts were positively selected by their ability to grow on the E. coli strain NM514 (Hyunh et al., 1985) . Library 1 was made from mRNA isolated from cells that had not been treated with actinomycin D and consisted of approximately 3 × 105 recombinant phage. After amplification this library was screened by hybridization with 32p-labelled PIV2 genomic eDNA (Grunstein & Hogness, 1975) . Positive phages were grown as plate lysates and the DNA was isolated using the method of Manfioletti & Schneider (1988) . Clones containing specific PIV2 genes were identified as described in Results. Insert size was estimated by agarose gel electrophoresis of EcoRI-digested cloned DNA.
Since no full-length inserts were identified in library 1 a second library was constructed. Library 2 was prepared with mRNA isolated from cells infected with PIV2 in the presence of actinomycin D and gave rise to 5 x 10 s discrete plaques in 2gtl0. Plaques containing specific PIV2 genes were identified by screening library 2 with 32p randomly primed inserts of clones, generated in library 1, that had been identified as containing specific gene sequences (see Results).
DNA sequencing. EcoRI restriction fragments from library 1 were cloned directly into the EcoRI site of M13mp8 and sequenced. However, the larger NotI-restricted fragments generated from library 2 were initially subcloned into pUC13. Colonies containing the appropriate insert were then grown in bulk, the plasmids were isolated using standard techniques (Maniatis et al., 1982) and fragmented using an MSE ultrasonic probe. After end repair, using T4 DNA polymerase, and size selection by agarose gel electrophoresis, the fragments were cloned into the Sinai site of M13mpl8. Sequencing was carried out using the method of Sanger et al. (1977) . Computer-assisted alignments and comparison of sequences with other related virus genes was carried out using the Staden programs (Staden, 1982a, b) on a DEC VAX computer.
Oligonucleotide synthesis and polymerase chain reaction (PCR).
Oligonucleotide synthesis was carried out using an Applied Biosystems oligonucleotide synthesizer and phosphoramidite chemistry. Oligonucleotides (i) 5' GAGCAAGTTCAGCCTGGTTAAGTCC 3', (ii) 5' CTTATGAGTATTTCTTCCAGGGTA 3' and (iii) 5' GGTTAGC-CAAAGCAATTAATGATTTTAATG 3' were used in the PCR as described in Results. Oligonucleotides (i) and (ii) hybridize to complementary strands flanking the unique EcoRI site on 2gtl0. Primer extension of these oligonucleotides runs towards the cloning site. Oligonucleotide (iii) is complementary to positions 342 to 371 of the PIV2 HN gene shown in Fig. 1 .
Results

Construction of eDNA libraries and identification of clones containing specific PIV2 genes
mRNA was isolated from PIV2-infected cells and, following eDNA synthesis, cloned into 2gtl0. Plaques were screened for PIV2 inserts using 32p-labelled eDNA made from randomly primed genomic RNA. Clones with PIV2 inserts were isolated and the size of the inserts was estimated by digestion of the clones with EeoRI followed by agarose gel electrophoresis. Phage with inserts of more than 500 bp were then characterized in terms of their ability to cross-hybridize with one another. By this means five independent groups of clones were identified. Inserts from representative phage were then cloned directly into M13mpl8 and sequenced. The predicted amino acid sequences so derived were compared to published parainfluenza virus sequences, including SV5, mumps virus and NDV, using DIAGON computer analysis (Staden, 1982b) . Phage containing inserts of the HN, P and M genes of PIV2 have so far been identified in this manner (data not shown).
Although library 1 proved extremely useful in identifying specific PIV2 genes by generating limited sequence data, no full-length clones corresponding to any PIV2 genes were identified in this library. Consequently, a second library was constructed using mRNA in which it had been demonstrated by Northern blot analysis that there was a high level of full-length HN mRNA (data not shown). Furthermore since actinomycin D inhibits cellular mRNA synthesis but not paramyxovirus mRNA synthesis (Paterson et al., 1984) , the proportion of plaques containing PIV2-specific inserts was increased by isolating the mRNA from cells infected in the presence of actinomycin D. Also restriction enzyme analysis of clones isolated from library 1 had demonstrated the presence of an EcoRI restriction site in the PIV2 HN gene. Consequently, in order to facilitate the future isolation and purification of full-length HN gene inserts the eDNA used in the construction of library 2 1930 1940 1950 1960 1970 1980 1990 was inserted into 2gtl0 in such a way as to generate flanking NotI restriction enzyme sites. The rationale for this was that since NotI recognizes an eight nucleotide palindromic sequence it would be unlikely that a NotI restriction enzyme site would be present in the HN gene sequence. Clones in library 2 that contained HN-specific sequences were identified by screening the library with a radiolabelled HN cloned insert that had been previously identified in library 1. Of 50 clones that contained HN gene sequences, eight had inserts of around 2 kbp. One of these inserts was subcloned into pUC 13, shotgun-cloned into M13mpl8 and sequenced. By this means the insert was sequenced on both strands and on average each base was sequenced in four independent M13 clones. However, sequence comparisons withthe HN gene of SV5 suggested that this insert was missing approximately 100 nucleotides from the 5' end of the gene. In order to facilitate the rapid identification of 2 clones that should contain the complete 5' end of the HN gene the clones were analysed, using the PCR, for the presence of 5' HN sequences. Two oligonucleotides were synthesized that were complementary to 2 sequences flanking the cloning site such that they could be used for primer extension into inserted sequences. A third oligonucleotide that was complementary to a previously determined sequence near the 5' end of the HN mRNA was also synthesized (see Methods). 2 clones containing HN gene inserts of approximately 2 kb were used with these oligonucleotides in PCRs. By this method a 3, clone was identified which gave a PCR product that was estimated to be approximately 400 bp by agarose gel electrophoresis. The PCR product was cloned directly into M13 and five independent clones, representing both strands, were sequenced without ambiguity. The complete nucleotide sequence of the HN gene, together with the deduced amino acid sequence of the protein, is presented in Fig. 1 .
GTTTTGGCTGTA~AGAATGTTATAGCATTcTGcTGTTTTTCCCATATG~GC~TCCTTc~cAccGAC~AGG~C~TT~CTCATCATTTACTG~GT~TTC~TC~AcTAAAG
Discussion
In this paper we report on the cloning and sequencing of the mRNA for the HN protein of PIV2. The deduced amino acid sequence predicts a protein of 571 amino acids. Hydrophobicity plots (Kyte & Doolittle, 1982) predicted that the membrane anchorage domain is located between amino acids 23 and 46 at the amino terminus of the protein. Although the protein has a calculated MT of 61 217, the Mr of the glycosylated HN protein has been estimated as 81K to 84K by SDS-PAGE (Randall & Young, 1988; Rydbeck et al., 1988) . No estimate of the Mr of the unglycosylated protein has been made as we have not been able to identify the unglycosylated protein in tunicamycin-treated cells (unpublished observations). However, by way of comparison the deduced amino acid sequence of the HN protein of mumps virus predicts a protein with a calculated Mr of 64 051, whereas the estimated Mr of the glycosylated HN is 74K to 79K (Waxam et al., 1988) . For SV5 the calculated Mr is 62134, while the glycosylated protein has an estimated Mr of 68K to 70K (Hiebert et al., 1985) . If glycosylation acceptor sites with the sequence Asn-(Pro/Cys)-(Thr/Ser) are ignored (Neuberger et al., 1972) then there are nine predicted glycosylation sites for PIV2 as compared to three for SV5 and five for mumps virus. It therefore seems likely that the relatively large difference between the calculated Mr of the HN protein of PIV2 and the estimated Mr of the glycosylated protein may be because the PIV2 protein is heavily glycosylated as compared to SV5 and mumps virus.
PIV2 shows 43% identical amino acid homology to SV5 and 40% homology to mumps virus, 30% of the amino acids being identical between all three viruses (Fig. 2) . The three P proteins also show approximately the same level of amino acid identity (Southern et al., 1990) . Given the degree of identity between SV5, PIV2 and mumps virus, it is possible that prior infection with Fig. 2 . Comparison of the aligned amino acid sequences of the HN proteins of PIV2, mumps virus (Waxam et al., 1988) and SV5 (Heibert et al., 1985) . Areas of the proteins which have stretches of amphipathic amino acids and hence may be targets for T cells (Margalit et al., 1987) are underlined. one virus may influence the outcome of infection with another. Thus, although there appear to be few antigenic sites that induce cross-reacting neutralizing antibody (Randall & Young, 1988 ), a greater degree of crossreactivity may be seen in T cell responses (for a review of how virus antigens are recognized by antibodies and T cells see Randall & Souberbielle, 1990) . Indeed a computer program used to predict likely T helper cell epitopes, by identifying stretches of amphipathic amino acids on proteins (Margalit et al., 1987) , predicted possible T cell epitopes in areas of identity between the HN proteins of PIV2, SV5 and mumps virus (Fig. 2) .
Since SV5 causes respiratory illness in dogs and monkeys, and because of the antigenic cross-reactivity observed between SV5 and PIV2, it has often been assumed that SV5 is the animal equivalent to human PIV2 (Pringle, 1987; Tsurudome et al., 1989) . However, the degree of identity between these two viruses is similar to that observed between PIV2 and mumps virus and also between SV5 and mumps virus. By way of contrast, the HN proteins of human PIV3 and bovine PIV3 share 80~o amino acid identity (Elango et al., 1986; Suzu et al.,  1987) . These results therefore demonstrate that although SV5 and PIV2 are closely related they should be considered as distinct virus types.
